Food and Drug Administration] approval. Without this competition, prices for GLP-1 receptor agonists will remain high for many years, reducing access for patients and raising health care costs. Egregious GLP-1 Prices to Increase Health Care Costs for Employers According to new research from the Business Group on Health and professional services firm Aon, health care costs for employers are expected to increase next year driven by Big Pharmas egregious prices for blockbuster GLP-1 drugs and out-of-control prices on gene and cell therapy treatments
Peptide & Bioregulator Jul 22, 2026 Glow Peptide: Benefits, Science, Side Effects, and How to Use It Glow Peptides are gaining attention for their potential role in collagen production, skin repair, and tissue regeneration
Bremelanotide, also called PT-141, is a metabolite of Melanotan II lacking the N-terminal acetyl-norleucine, and it carries a somewhat different receptor profile as a result
Cardiovascular disease Low activity levels of the selenoenzymes, glutathione peroxidases (GPx), have been reported in oxidative stress-related diseases, including cardiovascular disease (CVD) (90)